Orkin, Chloe Elion, Richard Thompson, Melanie Rockstroh, Juergen K Alvarez Bognar, Fernando Xu, Zhi J Hwang, Carey Sklar, Peter Martin, Elizabeth A
Published in
AIDS (London, England)
To evaluate changes in weight and BMI in adults with HIV-1 at 1 and 2 years after starting an antiretroviral regimen that included doravirine, ritonavir-boosted darunavir, or efavirenz. Post-hoc analysis of pooled data from three randomized controlled trials. We evaluated weight change from baseline, weight gain at least 10%, and increase in BMI af...
Huhn, Gregory D Crofoot, Gordon Ramgopal, Moti Gathe, Joseph Bolan, Robert Luo, Donghan Simonson, Richard Bruce Nettles, Richard E Benson, Carmela Dunn, Keith
...
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Most guidelines recommend rapid treatment initiation for patients with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection, but prospective US data are limited. The DIAMOND (NCT03227861) study using darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a phase 3 prospective study evaluating effi...
Chaussade, Hélène Tumiotto, Camille Le Marec, Fabien Leleux, Olivier Lefèvre, Lucile Lazaro, Estibaliz Lafon, Marie-Edith Nyamankolly, Elsa Duffau, Pierre Neau, Didier
...
Published in
Open Forum Infectious Diseases
A low level of darunavir resistance-associated mutation emergence in patients with virological failure during long term use of boosted darunavir. Confirmation of the robustness of this protease inhibitor in the ANRS CO3 Aquitaine cohort in a real life setting.
Liu, Zhanglong Tran, Trang T. Pham, Linh Hu, Lingna Bentz, Kyle Savin, Daniel A. Fanucci, Gail E.
Published in
Viruses
Multidrug resistance continues to be a barrier to the effectiveness of highly active antiretroviral therapy in the treatment of human immunodeficiency virus 1 (HIV-1) infection. Darunavir (DRV) is a highly potent protease inhibitor (PI) that is oftentimes effective when drug resistance has emerged against first-generation inhibitors. Resistance to ...
Darwish, Ibrahim A. Almehizia, Abdulrahman A. Radwan, Awwad A. Herqash, Rashed N.
Published in
Molecules
Darunavir (DRV) is a potent antiviral drug used for treatment of infections with human immunodeficiency virus (HIV). Effective and safe treatment with DRV requires its therapeutic drug monitoring (TDM) in patient’s plasma during therapy. To support TDM of DRV, a specific antibody with high affinity is required in order to develop a sensitive immuno...
Spinner, Christoph D Kümmerle, Tim Schneider, Jochen Cordes, Christiane Heiken, Hans Stellbrink, Hans-Jürgen Krznaric, Ivanka Scholten, Stephan Jensen, Björn Wyen, Christoph
...
Published in
Open Forum Infectious Diseases
The DUALIS phase-III study demonstrated non-inferiority of an effective and safe switch to dolutegravir combined with boosted darunavir (2DR) in suppressed people living with HIV as compared to continue 2 nucleoside reverse transcriptase inhibitors in combination with boosted darunavir (3DR).
Kala, Smriti Dunk, Caroline Acosta, Sebastian Serghides, Lena
Published in
Human reproduction (Oxford, England)
Does HIV protease inhibitor (PI)-based combination antiretroviral therapy (cART) initiated at periconception affect key events in early pregnancy, i.e. decidualization and spiral artery remodeling? Two PIs, lopinavir and darunavir, currently offered as cART options in HIV-positive pregnancies were evaluated, and we found that lopinavir-based cART, ...
Chen, Jun Xia, Lu Liu, Li Xu, Qingnian Ling, Yun Huang, Dan Huang, Wei Song, Shuli Xu, Shuibao Shen, Yingzhong
...
Published in
Open Forum Infectious Diseases
Background We aimed to evaluate the antiviral activity and safety of darunavir/cobicistat (DRV/c) in treating COVID-19 patients. Methods In this single-center, randomized, and open-label trial, mild patients with polymerase chain reaction (PCR)–confirmed COVID-19 were enrolled in Shanghai, China. Participants were randomized to receive DRV/c for 5 ...
Casado, José L Vizcarra, Pilar Blanco, José L Montejano, Rocío Negredo, Eugenia Espinosa, Nuria Montero, Marta Mena, Alvaro Palacios, Rosario Lopez, Juan C
...
Published in
International journal of STD & AIDS
Stroppa, Elisa Maria Toscani, Ilaria Citterio, Chiara Anselmi, Elisa Zaffignani, Elena Codeluppi, Mauro Cavanna, Luigi
Published in
Future Oncology
Background: We describe cancer patients with coronavirus disease-2019 (COVID-19) infection treated at the Piacenza’s general hospital (north Italy). Materials & methods: Twenty-five cancer patients infected by COVID-19 admitted at the Piacenza’s general hospital from 21 February to 18 March 2020. Outcome from the infection were compared with infec...